Biogen Idec Leukemia Combination Regimen is Effective
Posted on: Monday, 11 December 2006, 12:01 CST
Biogen Idec has reported promising data from a phase I/II study of lumiliximab in a regimen with chemotherapy and Rituxan for chronic lymphocytic leukemia patients.
Chemotherapy plus Biogen Idec's Rituxan is the emerging standard of care for this patient population.
When added to the chemotherapy/Rituxan combination regimen, lumiliximab demonstrated a 52% complete response rate in patients who have chronic lymphocytic leukemia (CLL) that was progressing after prior therapy. An overall response rate of 71% was also demonstrated.
In this study, lumiliximab appears to be well tolerated as compared to what would be expected from chemotherapy and Rituxan alone.
Complete response rate is a predictor of progression-free survival in CLL patients. Based on the positive results of the trial, Biogen Idec is initiating a more advanced trial evaluating the lumiliximab early next year.
The treatment regimen was used in this trial because it has been established as the emerging standard of care for CLL patients. A study conducted at The MD Anderson Cancer Center demonstrated that chemotherapy and Rituxan was an active and well-tolerated treatment for previously treated patients with CLL, and achieved a complete response rate of 25%.
Source: Datamonitor
Related Articles
- Responses After Completion of Therapy Increase Pixantrone Complete Remission (CR)/Unconfirmed Complete Remission (CRu) Rate to 24% and Overall Response Rate (ORR) to 40% Compared to 7% and 14% for Comparator Agents in Phase III EXTEND Trial in 3rd Line Th
- Micromet Presents Update on Blinatumomab's Response Rate and Duration in a Phase 1 Study in Non-Hodgkin's Lymphoma Patients
- Boston Scientific Data Show Real-World Survival Rates for Implantable Cardiac Device Patients Exceed Rates From Clinical Trials
- Interim Phase 2 Results of Open-Label Clinical Trial of Denosumab in Giant Cell Tumor of Bone Demonstrated 87 Percent Response Rate
- Genasense(R) Chemotherapy Program Yields High Response Rate in Patients With Stage 4 Melanoma
- ERBITUX(R) (Cetuximab) Data Demonstrate Improvements in Response Rate and Progression-Free Survival in Wild Type K-Ras Metastatic Colorectal Cancer Patients in First-Line Setting
- ONTAK(R) (Denileukin Diftitox) Achieves 49.1% Overall Response Rate in Phase III Trial of Cutaneous T-Cell Lymphoma (CTCL)
- Valeant Pharmaceuticals Announces Availability of Complimentary ``Managing Chemotherapy Side Effects For Dummies'' Cancer Chemotherapy Resource; Special Edition ``For Dummies''(R) Book Now Available for Cancer Chemotherapy Patients and Caregivers
- Three Studies Confirm Activity of ABRAXANE As First-Line Treatment in Non-Small Cell Lung Cancer and Show Higher Tumor Response Rates Than Current Standard of Care
- ADVENTRX Reports Positive Preliminary Phase II Trial Results With CoFactor in Metastatic Colorectal Cancer; Data Show Increased Response Rate and No Grade 3/4 Gastrointestinal or Hematological Toxicity
 |
 |
User Comments (0)
RSS Feeds